Venture Capital Deals and Investments
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Venture Capital Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
BridGene Biosciences Raises $28M in Series B+ Round Led by Bayland Capital
Series BVenture Capital

BridGene Biosciences Raises $28M in Series B+ Round Led by Bayland Capital

•October 16, 2025
•Oct 16, 2025
0

Participants

BridGene Biosciences

BridGene Biosciences

company

Biotechnology Innovation Organization

Biotechnology Innovation Organization

investor

ZoomInfo

ZoomInfo

investor

Deal Summary

BridGene Biosciences completed a $28M Series B+ financing to advance its small-molecule drug pipeline, including clinical-stage covalent TEAD inhibitor BGC-515. The round was led by Bayland Capital with participation from GTJA Investment Group, Proxima Ventures and existing investors Lapam Capital and Grains Valley Venture Capital.

0

Comments

Want to join the conversation?

Loading comments...